We are a groundbreaking immunotherapy venture studio. We accelerate early-stage R&D discovery and build drug discovery programs to create companies that cure diseases from COVID to Cancer.
We are a groundbreaking immunotherapy venture studio. We accelerate early stage R/D discovery and build programs and companies, to cure diseases from COVID to Cancer.
Our studio of experienced, immunology-focused drug developers maximizes value creation by forming multiple, thematically aligned startups to develop and commercialize immunotherapeutics. We partner with university-based collaborators to extend novel and untapped fundamental biological observations, create proof-of-concept data, and generate advanced development candidate packages using our expertise and internal laboratories.
A dysfunctional immune system is increasingly being recognized as a key factor, if not the factor, in the causal development and maintenance of a broad spectrum of diseases from cancer to infectious, autoimmune, and inflammatory diseases.
We focus on more efficiently developing and validating drug concepts into advanced development candidate packages that can be spun out into biotech companies or acquired by pharmaceutical companies for clinical development.
We are propelled by the immune archetype platform, developed by Max Krummel and colleagues, which characterizes and compares the archetypal immune states in health and disease, and provides key insights into the cause and consequence of the disease, and how to interconvert the immune archetype of a particulate tissue from disease to healthy.
Novel immunotherapeutics face a formidable therapeutic valley of death. Successfully navigating this valley provides tremendous value to patients and investors – typically the largest step-up in a program’s lifetime. We provide the neccessary R&D infrastructure to rapidly and effectively traverse this valley.
Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies.
With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.
They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.
Matthew Krummel, Ph.D. is the Chair of the UCSF ImmunoX Initiative (immunox.ucsf.edu) and holds the Robert E. Smith Endowed Chair in Pathology. His lab (krummellab.com) specializes in using real-time imaging to launch and test hypotheses related to how the immune system processes information and makes decisions. Key recent discoveries have included determining features of T cell membrane biology and motility that govern how they efficiently survey for antigens as well as the discovery of archetypal collections of immune systems in cancer, notably those involving networks of cells built around stimulatory dendritic cells. His work spans scales from membrane organization, to cell biology, to entire immune systems. He received his Ph.D. at the University of California, Berkeley and did postdoctoral studies at Stanford University.
Dr. Krummel drives collaborative science: he founded a microscopy ‘collaboratory’ at UCSF which unites ‘shared’ technical personnel and he developed a novel industry consortium-funded project (immunoprofiler.org) which unites studies of over 15 cancer indications to understand the biology of individual patients. Together with other UCSF faculty, he founded the ImmunoX initiative, a radical collaboration platform focused on methods and data sharing as a means to accelerate discovery and cures. His initiative also emphasizes public outreach and interaction as a means to disseminate the value of science. Dr. Krummel’s work has led to multiple clinical advances including discovering anti-CTLA-4 ‘checkpoint blockade’ drugs (over 100,000 patients treated) and new next-generation immunotherapies through Pionyr Immunotherapeutics, and now Foundery Innovations, ventures that he co-founded and which have extensive academic-industry collaboration. The aim of all of his research is to understand and apply the immune system to improve human health.
Michel, Foundery Innovations CEO, has extensive scientific and executive administrative experience in the pharmaceutical and biotech industries, leading drug development from discovery through the early clinical stage, with a focus on therapies for cancer, chronic viral, autoimmune, and inflammatory diseases. He has over thirty years of leadership, innovation, team-building, collaboration, fundraising, and management experience in biologics and small molecule drug development, and over twenty-five years of experience directing basic and applied research at several companies, including Pionyr Immunotherapeutics, Gilead Sciences, Merck Research Laboratories, Schering-Plough Research Institute (acquired by Merck, Inc), Organon BioSciences (acquired by Schering-Plough), and ImmunoGen Inc., as well as a faculty member for ten years at the Dana-Farber Cancer Institute and Harvard Medical School. He played key roles in advancing multiple novel and biosimilar biologics into clinical development, including the first FDA approved immunotherapy, IFN-alpha2/IntronA®, and the anti-PD-1 immuno-oncology drug Keytruda®. He received his Ph.D. degree from the University of Zurich, Switzerland, and his postdoctoral training in the Division of Tumor Biology at the Dana-Farber Cancer Institute.
Sriram is an accomplished researcher with nearly 15 years of biopharmaceutical research experience developing biological and small molecule therapeutics against tumor immunotherapy targets. Prior to joining Max and Michel in starting Foundery, Sriram was at Pionyr Immunotherapeutics for over four years from the early stages. At Pionyr, Sriram played a key role in helping build the research team, leading the operational move from the incubator space to an independent facility, and serve as nonclinical lead for PY314 program. Sriram was also the author, editor, and coordinator of all regulatory filings including pre-IND and IND. Prior to Pionyr, Sriram was at Gilead Sciences for close to three years. Sriram established and successively led several immuno-oncology programs at Gilead Sciences and Merck. At Merck Research Laboratories (formerly the Schering-Plough Biopharma prior to its acquisition by Merck), Sriram also served as the cross-site pharmacology lead for all immuno-oncology programs, including the anti-PD-1 antibody Keytruda. Sriram received his Ph.D. degree in Biochemistry and Immunology from the University of Madras, India, and completed his post-doctoral training in immunology at the Indiana University School of Medicine.